Table 1. Patient characteristics.
| N | 203 |
| Patient sex | |
| Male | 116 (57%) |
| Female | 87 (43%) |
| Median patient age, years (range) | 58 (21-73) |
| AML cytogenetic risk | |
| Favorable | 4 (2%) |
| Intermediate | 142 (70%) |
| Adverse | 42 (21%) |
| Failed | 15 (7%) |
| Number of induction courses to achieve CR1 | |
| 1 | 133 (66%) |
| >1 | 70 (34%) |
| Interval from diagnosis to achieve CR1, days (range) | 51 (21-350) |
| Interval from CR1 to transplantation, days (range) | 115 (15-351) |
| Median donor age, years (range) | 34 (19-61) |
| Donor sex | |
| Male | 135 (67%) |
| Female | 68 (33%) |
| Female donor to male recipient | 32 (16%) |
| Patient CMV serosatus | |
| Negative | 94 (46%) |
| Positive | 109 (54%) |
| Donor CMV serostatus | |
| Negative | 134 (66%) |
| Positive | 69 (34%) |
| Conditioning | |
| Chemotherapy-based | 143 (70%) |
| Fludarabine + busulfan | 110 |
| Fludarabine + treosulfan | 14 |
| Fludarabine + melphalan | 12 |
| Other | 7 |
| TBI-based | 60 (30%) |
| In-vivo T-cell depletion | 166 (82%) |
| ATG | 153 |
| Campath | 13 |
| GVHD prophylaxis | |
| CsA + Mtx | 129 (64%) |
| CsA + MMF | 69 (34%) |
| Other | 5 (2%) |
| Median CD34(+) dose, cells per kilogram x 10^6 (range) | 6.53 (1.34-41.3) |
| Interquartile range | 5.0-8.25 |
| Median CD3(+) dose, cells per kilogram x 10^6 (range) | 250 (50-885) |
| Interquartile range | 175.4-347 |
| Median year of transplantation, range | 2011 (2000-2012) |
| Median follow-up, months (range) | 22 (3-105) |
Abbreviations: AML – acute myeloid leukemia; CR1 – first complete remission; CMV – cytomegalovirus; TBI - total body irradiation; ATG - antithymocyte globulin; GVHD – graft-versus-host disease; CsA – cyclospirin A; Mtx – methotrexate; MMF - mycophenolate mofetil